Clinical trial NCT02599961: Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)
Official title: An Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency Syndrome
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Glucose Transporter Type 1 Deficiency Syndrome
Keywords: Glut 1 DS
Lead sponsor: Ultragenyx Pharmaceutical Inc
Sponsor class: INDUSTRY
First posted: 2015-11-09
Enrollment: 15
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of the study is to evaluate the long-term safety of UX007 in Glut1 DS participants.

Detailed description: The study will enroll up to 40 pediatric, adolescent and adult Glut 1 DS participants who have completed the UX007G-CL201 (NCT019933186) study and, at the discretion of the Sponsor, additional participants from other clinical studies, investigator sponsored trials (ISTs), or expanded access/compassionate use treatment.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of Glut 1 DS confirmed by cerebrospinal fluid glucose concentration. erythrocyte 3-O-methyl-D-glucose uptake assay, or solute carrier family 2 member 1 (SLC2A1) molecular genetic testing (Information obtained from Medical Records)
* Males and females aged at least 1 year old at the time of informed consent
* Completion of UX007G-CL201 study (NCT01993186). Glut1 DS patients who received UX007/triheptanoin treatment as apart of clinical studies, ISTs or expanded access/compassionate use treatment programs may be eligible at the discretion of the Sponsor
* Provide written informed consent or verbal assent (if possible) with written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research related procedures
* Must, in the opinion of the investigator, be willing and able to complete all aspects of the study, and comply with accurate completion of the seizure diary
* Females of childbearing potential must have a negative urine pregnancy test at Baseline and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have not experienced menarche, are post-menopausal (defined as having no menses for at least 12 months without an alternative medical cause), or are permanently sterile due to total hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
* Participants of child-bearing potential or fertile males with partners of child-bearing potential who are sexually active must consent to use a highly-effective method of contraception as determined by the investigator from the period following the signing of the informed consent through 30 days after last dose of study drug.

Exclusion Criteria:

* Any known hypersensitivity to triheptanoin, that in the judgement of the investigator, places the subject at an increased risk for adverse effects
* History of, or current suicidal ideation, behavior and/or attempts
* Pregnant and/or breast feeding an infant
* Unwilling or unable to discontinue use of prohibited medication (barbiturates, pancreatic lipase inhibitors) or other substance that may confound study objectives. Use of up to 3 concomitant antiepileptic drugs is allowed, provided dose has been stable at least 14 days prior to Baseline
* Use of any Investigational Product, drug or supplement (other than UX007) within 30 days prior to Baseline, or at any time during the study
* Has a condition of such severity and acuity, in the opinion of the investigator, that it warrants immediate surgical intervention or other treatment
* Has a concurrent disease or condition, or laboratory abnormality that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or introduce additional safety concerns

Primary outcomes:
measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Discontinuations Due to TEAEs, and Deaths
timeFrame: From first dose of study drug up to 36 months. The mean (SD) treatment duration was 667.9 (357) days.
Secondary outcomes:
measure: Change From Baseline Over Time in Overall Seizure Frequency Per 4 Weeks
timeFrame: Baseline (from NCT01993186), Month 0-3, Month 4-6, Month 7-9, Month 10-12, Month 13-18, Month 19-24, Month 25-30, Month 31-36
measure: Change From Baseline Over Time in CNS Total Score
timeFrame: Baseline (from NCT01993186), Month 0, Month 6, Month 12, Month 24, Month 36
measure: Change From Baseline Over Time in SF-10 Health Survey for Children Physical Summary Score
timeFrame: Baseline (from NCT01993186), Month 0, Month 6, Month 12, Month 18, Month 24, Month 30
measure: Change From Baseline Over Time in SF-10 Health Survey for Children Psychosocial Summary Score
timeFrame: Baseline (from NCT01993186), Month 0, Month 6, Month 12, Month 18, Month 24, Month 30
measure: Change From Baseline Over Time in SF-12v2 Health Survey PCS Score
timeFrame: Baseline (from NCT01993186), Month 0, Month 6, Month 12, Month 18
measure: Change From Baseline Over Time in SF-12v2 Health Survey MCS Score
timeFrame: Baseline (from NCT01993186), Month 0, Month 6, Month 12, Month 18
Other outcomes:
Locations:
city: Aurora
country: United States
facility: Children's Hospital Colorado - University of Colorado, Denver, School of Medicine
state: Colorado
city: Miami
country: United States
facility: Miami Children's Hospital
state: Florida
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
city: Fort Worth
country: United States
facility: Cook Children's Medical Center
state: Texas
city: Seattle
country: United States
facility: Seattle Children's Hospital
state: Washington
city: Heidelberg
country: Australia
facility: Melbourne Brain Centre
state: Victoria
city: Copenhagen
country: Denmark
facility: Copenhagen University Hospital
city: Barcelona
country: Spain
facility: Hospital Sant Joan De Deu
city: Newcastle upon Tyne
country: United Kingdom
facility: The Newcastle upon Tyne Hospitals NHS Foundation Trust
Study officials:
affiliation: Ultragenyx Pharmaceutical Inc
name: Medical Director
role: STUDY_DIRECTOR
References: